Nvidia and Genentech are teaming up for an exciting, long-term collaboration that aims to revolutionize drug discovery through the cutting-edge capabilities of artificial intelligence, including generative AI.
In simple terms, Nvidia wants to supercharge Genentech’s advanced AI research programs by turning its generative AI models and algorithms into a powerful “next-gen AI platform.” The goal? To speed up the discovery of new therapies and medicines.
Genentech already boasts its own machine learning algorithms, but it’s turning to Nvidia to level up. They plan to utilize Nvidia’s DGX Cloud, a training-as-a-service platform that harnesses the AI prowess of Nvidia’s specialized hardware and software, including Nvidia BioNemo.
BioNemo, now available as a training service, is a specific platform designed to simplify, accelerate, and scale up generative AI applications for computational drug discovery. With the help of Nvidia’s DGX Cloud, researchers can pretrain or fine-tune advanced models.
Nvidia isn’t just providing technology; they’re sharing their computing expertise. They’ll collaborate closely with Genentech’s computational scientists to optimize and scale up AI models. This collaboration isn’t just a win for Genentech; it might also lead to improvements in Nvidia’s platforms.
Genentech acknowledges that drug discovery is a lengthy and complex process with a high level of uncertainty. AI, they believe, can be a game-changer, making drug discovery more predictable, cost-effective, and boosting the long-term success rate of research and development programs.
Aviv Regev, EVP and Head of Research and Early Development at Genentech, is enthusiastic about unlocking scientific discoveries rapidly. He sees the collaboration with Nvidia as a way to optimize drug discovery and development for treatments that can transform lives.
Genentech’s AI teams are actively working on foundational models in various research areas, aiming to gain insights for target and drug discovery. Their “lab in a loop” initiative, focused on using experimental data to enhance computational models, will benefit from Nvidia’s platforms.
This collaboration allows Genentech to assess predictions more rapidly and continually improve its models, ultimately leading to more effective therapies.
Crucially, the collaboration respects data privacy. Nvidia won’t access Genentech’s data without explicit permission for a specific project.
This partnership reflects the fusion of science and technology, a cornerstone of breakthroughs in biomedical research.
Leave a Reply